Equities researchers at HC Wainwright dropped their FY2025 earnings per share estimates for Larimar Therapeutics in a ...

Larimar Therapeutics, Inc. (Nasdaq: LRMR) has announced significant progress in its nomlabofusp program for Friedreich’s ...

FDA stated in written correspondence for a START pilot program meeting that it is open to considering skin FXN concentration as a reasonably ...

Larimar Therapeutics (NASDAQ:LRMR – Get Free Report) had its target price increased by HC Wainwright from $15.00 to $16.00 in ...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at ...

Baird lowered the firm’s price target on Larimar Therapeutics (LRMR) to $10 from $13 and keeps an Outperform rating on the shares. Th efirm ...

Explore Larimar Therapeutics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for LRMR. Larimar Therapeutics reports promising FXN level increases with 25 mg ...

The latest price target for Larimar Therapeutics (NASDAQ:LRMR) was reported by Guggenheim on March 25, 2025. The analyst firm set a price target for $26.00 expecting LRMR to rise to within 12 ...

BALA CYNWYD, Pa. (AP) — BALA CYNWYD, Pa. (AP) — Larimar Therapeutics, Inc. (LRMR) on Monday reported a loss of $28.8 million in its fourth quarter. The Bala Cynwyd, Pennsylvania-based company said it ...

March 24, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases ...

BALA CYNWYD, Pa. (AP) — BALA CYNWYD, Pa. (AP) — Larimar Therapeutics, Inc. (LRMR) on Monday reported a loss of $28.8 million in its fourth quarter. The Bala Cynwyd, Pennsylvania-based company ...